Amgen Inc. is navigating a complex landscape following its $27.8 billion acquisition of Horizon Therapeutics while preparing for a first-quarter earnings report on April 30, 2026, where a 3.1% decline in earnings per share is expected. The biotech giant is also under investigation and facing a securities class action lawsuit, which may raise concerns among investors who have incurred significant losses. Amid these challenges, analysts are maintaining a Hold rating on Amgen, reflecting cautious optimism as the company expands its operations and portfolio.
“According to OpenSecrets, Sen. Michael Bennet has received pharma/health product PAC donations including Pfizer ($10k), Merck ($17.5k), Amgen ($15k), AbbVie ($10k), plus nearly $1M total from health sector PACs over his Senate career.”
“$ZLAB (+2.4% pre) Zai Lab (ZLAB), Amgen $AMGN Partner to Evaluate Combination Lung Cancer Therapy; Zai Lab stock rises on positive trial data for cancer drug”
“Global drugmaker Pfizer and biotech firm Amgen, each valued at over HK$1T ($153B), are among 22 strategic enterprises planning to open or expand offices in Hong Kong, the South China Morning Post reported.”
“AMGEN ANNOUNCES RETIREMENT OF DAVID M. REESE, EXECUTIVE VICE PRESIDENT AND CHIEF TECHNOLOGY OFFICER.”
“Amgen | 22 | 0.17 | 2836 | Biotech | Health | AMGN”
“In September 2020, Amgen partnered with Lilly to manufacture COVID-19 antibody therapies.”
“Amgen was named among America's Most Innovative Companies in 2026.”
“Amgen is set to report its first-quarter 2026 financial results on April 30, with expectations of a 3.1% decline in earnings per share (EPS).”
“Recent insider selling and an upcoming management reorganization may signal caution among investors as the company prepares for this pivotal earnings call.”
“Analyst Canaccord Genuity has initiated a rating on AMGN with a Hold recommendation and announced a price target of 366.”
“Amgen (NASDAQ:AMGN) today announced that it will report its first quarter 2026 financial results on Thursday, April 30, 2026, after the close of the U.S. financial markets.”
“Amgen is advancing a broad and deep pipeline and portfolio of medicines to treat cancer, inflammatory conditions, rare diseases, heart disease and obesity and obesity-related conditions.”
